Bayer, Draws

Bayer Draws Fresh Price Targets From Two Brokers as Missouri Judge Signs Off on Roundup Fund

Published on 11/22/2026 at 13:01 | Editorial boerse-global.de
Kepler Cheuvreux, Berenberg and Jefferies moved on Bayer within days; a Missouri court granted final approval to the $7.25 billion Roundup settlement.
Bayer, Draws, Fresh, Price, Targets, From, Two, Brokers, Missouri, Judge Illustration mit AI erstellt.

Two European research houses have moved on Bayer within 24 hours of each other, and neither is telling clients to sell. Kepler Cheuvreux lifted its target to 68 euros from 59 on Thursday while keeping a Buy rating, and Jefferies restated a Hold with a 48.50-euro target unchanged. Sandwiched between them, Berenberg on Wednesday raised its own target to 62.00 euros from 53.50 euros but stayed at Hold.

The Berenberg note points to momentum in the pharmaceuticals division and to possible proceeds from a Monsanto initial public offering toward the end of the decade. Kepler's more bullish stance leaves its target 5.50 euros above Berenberg's revised figure and nearly 20 euros clear of Jefferies.

Missouri court makes the Roundup cap final

The legal backdrop shifted on Friday, when a court in the US state of Missouri granted final approval to the Roundup collective settlement worth 7.25 billion US dollars. The ruling remains subject to appeal. Monsanto is to pay out as much as that sum over up to 21 years, including amounts already disbursed, under a long-term compensation programme covering existing and potential future claims tied to alleged non-Hodgkin lymphoma.

Should investors sell immediately? Or is it worth buying Bayer?

Bayer called the decision a milestone in its strategy to contain pending and possible future litigation. The shares reacted positively, rising 1.2% on Friday. In the post-market Tradegate session immediately after the ruling, the stock had initially added 3%.

A first-in-class stroke drug clears the FDA

Separately, Bayer said in November that the US Food and Drug Administration had approved Asundexian under the brand name Sunharbo for reducing the risk of stroke. The company describes the treatment as the world's first approved factor XIa inhibitor. The FDA clearance covers lowering the risk of recurrent strokes.

Guidance raised alongside quarterly figures

With its quarterly statement of 3 November, Bayer improved its full-year outlook. For the third quarter of 2026 the group reported revenue of 10.1 billion euros and EBITDA before special items of 1.62 billion euros.

Ad

Bayer Stock: New Analysis - 22 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70544260 |